Key Product Details

Species Reactivity

Validated:

Rat

Cited:

Human, Mouse, Rat

Applications

Validated:

Immunohistochemistry, Western Blot

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Immunocytochemistry

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
View all CD34 Primary Antibodies »

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant rat CD34
Glu37-Ile293
Accession # NP_001100672

Specificity

Detects rat CD34 in direct ELISAs and Western blots. In these formats, less than 1% cross-reactivity with recombinant porcine CD34 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Rat CD34 Antibody

CD34 antibody in Rat Liver by Immunohistochemistry (IHC-Fr).

CD34 in Rat Liver.

CD34 was detected in perfusion fixed frozen sections of rat liver using 15 µg/mL Rat CD34 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4117) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Detection of Rat CD34 by Immunohistochemistry

Detection of Rat CD34 by Immunohistochemistry

Cell composition of the neointima after patch venoplasty. (A) Representative Western blot showing expression of CD34, VEGFR2, alpha ‐actin, CD68, CD45, vimentin and GAPDH in the control IVC (vein), preimplantation patch (day 0), and neointima at day 7 or 30; n = 3. (B) Immunofluorescence analysis of the neointima at days 7 or 30 and control IVC (vein). Upper row, merge of CD34 (green), VEGFR2 (red), and DAPI (blue). Lower row, merge of CD34 (green), alpha ‐actin (red), and DAPI (blue); scale bar, 50 μm; L, lumen; N, neointima; yellow arrow shows colocalization; n = 4. (C) Immunohistochemical analysis of the neointima at day 0 (upper row), day 7 (center row), or day 30 (lower row). Day 0 (upper row) shows control preimplantation patch without neointima. Analysis for: first column, CD31; second column, alpha ‐actin; third column, CD68; fourth column, CD45; fifth column, vimentin. P, patch; L, lumen; N, neointima; yellow arrows show the positive cells. Scale bar, 100 μm; n = 4. (D) Bar graph showing endothelial confluence; P < 0.0001, ANOVA. *P < 0.0001 versus day 0; **P = 0.0048 versus day 7 (post hoc test); n = 4. (E) Bar graph showing the mean neointimal smooth muscle cell (SMC) density; P < 0.0001, ANOVA. *P < 0.0001 versus day 0 (post hoc test); n = 4. (F–H) Bar graphs showing percentage of neointimal CD45, CD68 and vimentin positive cells(mean number of cells counted in 4 high power fields); P < 0.0001, ANOVA). *P < 0.0001 versus day 0; **P < 0.01 versus day 7 (post hoc test); n = 4. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/27354544), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Rat CD34 by Western Blot

Detection of Rat CD34 by Western Blot

Cell composition of the neointima after patch venoplasty. (A) Representative Western blot showing expression of CD34, VEGFR2, alpha ‐actin, CD68, CD45, vimentin and GAPDH in the control IVC (vein), preimplantation patch (day 0), and neointima at day 7 or 30; n = 3. (B) Immunofluorescence analysis of the neointima at days 7 or 30 and control IVC (vein). Upper row, merge of CD34 (green), VEGFR2 (red), and DAPI (blue). Lower row, merge of CD34 (green), alpha ‐actin (red), and DAPI (blue); scale bar, 50 μm; L, lumen; N, neointima; yellow arrow shows colocalization; n = 4. (C) Immunohistochemical analysis of the neointima at day 0 (upper row), day 7 (center row), or day 30 (lower row). Day 0 (upper row) shows control preimplantation patch without neointima. Analysis for: first column, CD31; second column, alpha ‐actin; third column, CD68; fourth column, CD45; fifth column, vimentin. P, patch; L, lumen; N, neointima; yellow arrows show the positive cells. Scale bar, 100 μm; n = 4. (D) Bar graph showing endothelial confluence; P < 0.0001, ANOVA. *P < 0.0001 versus day 0; **P = 0.0048 versus day 7 (post hoc test); n = 4. (E) Bar graph showing the mean neointimal smooth muscle cell (SMC) density; P < 0.0001, ANOVA. *P < 0.0001 versus day 0 (post hoc test); n = 4. (F–H) Bar graphs showing percentage of neointimal CD45, CD68 and vimentin positive cells(mean number of cells counted in 4 high power fields); P < 0.0001, ANOVA). *P < 0.0001 versus day 0; **P < 0.01 versus day 7 (post hoc test); n = 4. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/27354544), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD34 by Immunohistochemistry

Detection of CD34 by Immunohistochemistry

Chronic DEN-induced hepatocarcinogenesis is associated with hypoxia. (a) Timeline protocol of the DEN-induced cirrhotic rat model of HCC. Seven-week-old Fisher 344 rats were injected weekly by DEN (50 mg/kg per week); 8 w indicates 8 weeks of DEN injections, 14 w indicates 14 weeks of DEN injections, and 14 + 6 w indicates 14 weeks of DEN injections followed by 6 weeks of no DEN injections. The arrows indicate the day of tissue harvest. (b) Representative pictures of the liver at 14 + 6 w from the rat without DEN treatment (upper panel) and the rat chronically treated with DEN (lower panel). (c) Representative images of the liver from rats untreated (upper panels) or treated with DEN injections (as above, lower panels). Histopathological sections stained with nuclear Cyclin D1 (20× magnification, left panels), with Sirius red (middle panels), and with anti-CD34 immunofluorescence (right panels). (d) Heatmap showing the single-sample Gene Set Enrichment Analysis (GSEA) scores for the Hypoxia Hallmarks gene set. (e–g) GSEA plots of differentially expressed genes from livers of DEN-treated versus untreated (NoDEN) rats at 14 weeks ((e): non-tumor tissue) and 14 + 6 weeks ((f): non-tumor tissue, (g): tumor tissue), showing the enrichment of genes associated with the response to low oxygen levels (Hypoxia-Hallmarks). NES, normalized enrichment score; FDR, false discovery rate; w, weeks. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35805134), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD34 by Immunohistochemistry

Detection of CD34 by Immunohistochemistry

Chronic DEN-induced hepatocarcinogenesis is associated with hypoxia. (a) Timeline protocol of the DEN-induced cirrhotic rat model of HCC. Seven-week-old Fisher 344 rats were injected weekly by DEN (50 mg/kg per week); 8 w indicates 8 weeks of DEN injections, 14 w indicates 14 weeks of DEN injections, and 14 + 6 w indicates 14 weeks of DEN injections followed by 6 weeks of no DEN injections. The arrows indicate the day of tissue harvest. (b) Representative pictures of the liver at 14 + 6 w from the rat without DEN treatment (upper panel) and the rat chronically treated with DEN (lower panel). (c) Representative images of the liver from rats untreated (upper panels) or treated with DEN injections (as above, lower panels). Histopathological sections stained with nuclear Cyclin D1 (20× magnification, left panels), with Sirius red (middle panels), and with anti-CD34 immunofluorescence (right panels). (d) Heatmap showing the single-sample Gene Set Enrichment Analysis (GSEA) scores for the Hypoxia Hallmarks gene set. (e–g) GSEA plots of differentially expressed genes from livers of DEN-treated versus untreated (NoDEN) rats at 14 weeks ((e): non-tumor tissue) and 14 + 6 weeks ((f): non-tumor tissue, (g): tumor tissue), showing the enrichment of genes associated with the response to low oxygen levels (Hypoxia-Hallmarks). NES, normalized enrichment score; FDR, false discovery rate; w, weeks. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35805134), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Rat CD34 Antibody

Application
Recommended Usage

Immunohistochemistry

5-15 µg/mL
Sample: Perfusion fixed frozen sections of rat liver

Western Blot

0.1 µg/mL
Sample: Recombinant Rat CD34

Reviewed Applications

Read 4 reviews rated 3.8 using AF4117 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CD34

Rat CD34 is a 80-100 kDa type I transmembrane glycoprotein that belongs to the CD34/Podocalyxin family of sialomucins. It is a widely used marker of activated hematopoietic stem/progenitor cells and is also expressed on adult vascular endothelial cells. Mature rat CD34 is predicted to be a 352 amino acid (aa) protein with a 257 aa extracellular domain (ECD) (aa 35-291) and 74 aa cytoplasmic tail (aa 313-386). Over the region used as immunogen, rat CD34 shares 83% and 57% aa identity with mouse and human CD34, respectively.

Alternate Names

CD34, HPCA1

Entrez Gene IDs

947 (Human); 12490 (Mouse); 305081 (Rat); 397160 (Porcine); 415130 (Canine)

Gene Symbol

CD34

UniProt

NP_001100672

Additional CD34 Products

Product Documents for Rat CD34 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Rat CD34 Antibody

For research use only

Citations for Rat CD34 Antibody

Customer Reviews for Rat CD34 Antibody (4)

3.8 out of 5
4 Customer Ratings
5 Stars
0%
4 Stars
75%
3 Stars
25%
2 Stars
0%
1 Stars
0%

Have you used Rat CD34 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card
Showing  1 - 4 of 4 reviews Showing All
Filter By:
Clear Filters X
  • Rat CD34 Antibody
    Name: Anonymous
    Application: Immunohistochemistry
    Sample Tested: Eye lens tissue
    Species: Rabbit
    Verified Customer | Posted 05/15/2018
  • Name: Anonymous
    Application: Immunohistochemistry-Paraffin
    Sample Tested: See PMID 25072110
    Species: Rat
    Verified Customer | Posted 01/08/2015
  • Name: Anonymous
    Application: Immunohistochemistry-Paraffin
    Sample Tested: See PMID 22361334
    Species: Rat
    Verified Customer | Posted 01/08/2015
  • Name: Anonymous
    Application: Immunocytochemistry
    Sample Tested: See PMID 24670794
    Species: Rat
    Verified Customer | Posted 01/08/2015

There are no reviews that match your criteria.

Showing  1 - 4 of 4 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies